Reuters logo
BRIEF-Bio-Path holdings presents results showing potential of BP1002
April 5, 2017 / 12:17 PM / 5 months ago

BRIEF-Bio-Path holdings presents results showing potential of BP1002

April 5 (Reuters) - Bio Path Holdings Inc

* Bio-Path holdings presents results showing potential of BP1002 as treatment for aggressive non-hodgkin’s lymphoma

* Bio-Path - announced results of preclinical in vitro, in vivo studies supporting potential of BP1002 in treating aggressive non-hodgkin’s lymphoma (nhl)

* BP1002 was shown to have strong anti-NHL activity in each of the studies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below